Highline Capital Management, L.P. Catalent, Inc. Transaction History

Highline Capital Management, L.P.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$119.57 - $139.07 $6.07 Million - $7.06 Million	-50,744 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$85.88 - $105.36 $842,998 - $1.03 Million	-9,816 Reduced 16.21%	50,744 $5.28 Million
Q3 2020 Nov 16, 2020	SELL	$72.74 - $92.5 $1.67 Million - $2.12 Million	-22,970 Reduced 27.5%	60,560 $5.19 Million
Q2 2020 Aug 14, 2020	SELL	$48.02 - $79.04 $24.8 Million - $40.8 Million	-515,910 Reduced 86.07%	83,530 $6.12 Million
Q1 2020 May 15, 2020	BUY	$36.95 - $62.95 $299,295 - $509,895	8,100 Added 1.37%	599,440 $31.1 Million
Q4 2019 Feb 14, 2020	SELL	$47.06 - $56.64 $21.8 Million - $26.3 Million	-464,203 Reduced 43.98%	591,340 $33.3 Million
Q3 2019 Nov 14, 2019	SELL	$47.45 - $58.05 $47.5 Million - $58.1 Million	-1,001,166 Reduced 48.68%	1,055,543 $50.3 Million
Q2 2019 Aug 14, 2019	BUY	$39.26 - $54.21 $80.7 Million - $111 Million	2,056,709 New	2,056,709 $111 Million

485

160M

364K

837K

Ticker CTLT
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 179,896,000
Market Cap $10.5B
Description
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products,...

Get notified when there are updates to the investment portfolio of Highline Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Highline Capital Management, L.P. with notifications on news.